Author:
Boeke Jef D.,Burns Kathleen H.,Chiappinelli Katherine B.,Classon Marie,Coffin John M.,DeCarvalho Daniel D.,Dukes Joseph D.,Greenbaum Benjamin,Kassiotis George,Knutson Sarah K.,Levine Arnold J.,Nath Avindra,Papa Sophie,Rios Daniel,Sedivy John,Ting David T.
Abstract
AbstractIn November 2022 the first Dark Genome Symposium was held in Boston, USA. The meeting was hosted by Rome Therapeutics and Enara Bio, two biotechnology companies working on translating our growing understanding of this vast genetic landscape into therapies for human disease. The spirit and ambition of the meeting was one of shared knowledge, looking to strengthen the network of researchers engaged in the field. The meeting opened with a welcome from Rosana Kapeller and Kevin Pojasek followed by a first session of field defining talks from key academics in the space. A series of panels, bringing together academia and industry views, were then convened covering a wide range of pertinent topics. Finally, Richard Young and David Ting gave their views on the future direction and promise for patient impact inherent in the growing understanding of the Dark Genome.
Publisher
Springer Science and Business Media LLC